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Context: Gestational diabetes mellitus (GDM), defined as any degree of glucose intolerance with first
recognition during pregnancy, is a heterogeneous form of diabetes characterized by various degrees of
b-cell dysfunction.
Objectives: We aimed to estimate the prevalence of possibly pathogenic variants in the maturity-
onset diabetes of the young genes GCK, HNF1A, HNF4A, HNF1B, and INS among women with
GDM. Furthermore, we examined the glucose tolerance status in variant carriers vs noncarriers at
follow-up.
Design, Setting, and Patients:We sequenced the coding regions and intron/exon boundaries ofGCK,
HNF1A, HNF4A, HNF1B, and INS using targeted region capture and next-generation sequencing in
354 Danish women with diet-treated GDM. Glucose tolerance was examined at follow-up 10 years after
the index pregnancy.
Main Outcome Measures: The prevalence of possibly pathogenic variants in GCK, HNF1A, HNF4A,
HNF1B, and INS was estimated, and differences in anthropometric traits, high-sensitivity C-Reactive
Protein (CRP), and glucose metabolism were measured.
Results: At baseline, 17 possibly disease-causing variants were found in 21 women, revealing a
combinedGCK,HNF1A,HNF4A,HNF1B, and INS variant prevalence of 5.9% (95% confidence interval:
3.5% to 8.4%). At follow-up, 15 out of 135 women with diabetes (11%) were carriers of variants in GCK,
HNF1A, HNF4A, HNF1B, or INS.
Conclusions:Almost 6% of Danish womenwith diet-treatedGDMhave possibly pathogenic variants in
GCK, HNF1A, HNF4A, HNF1B, or INS. These women are at high risk of developing diabetes after
pregnancy. Thus screening for variants in GCK, HNF1A, HNF4A, HNF1B, and INS should be con-
sidered among women with GDM.
Abbreviations: BMI, body mass index; CI, confidence interval; GADA, glutamic acid decarboxylase antibody; GDM, gestational
diabetes mellitus; hsCRP, high-sensitivity CRP; IFG, impaired fasting glycemia; IGT, impaired glucose tolerance; MODY, maturity-
onset diabetes of the young; OHA, oral hyperglycemic agent.
Received 5 January 2017
Accepted 24 April 2017
First Published Online 27 April 2017
June 2017 | Vol. 1, Iss. 6
doi: 10.1210/js.2017-00040 | Journal of the Endocrine Society | 681–690
Downloaded from https://academic.oup.com/jes/article-abstract/1/6/681/3769967
by Kobenhavns Universitets user
on 08 March 2018
Copyright © 2017 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
Freeform/KeyWords:monogenic diabetes, gestational diabetes, MODY, genes, genetic screening
Gestational diabetes mellitus (GDM) defined as any degree of glucose intolerance with first
recognition during pregnancy [1] is a frequent pregnancy complication. The prevalence of
GDMwas 2.4% in 2000 among 5,235 women in Denmark [2] and is globally affecting between
1% and 28% of all pregnancies with large country-wise differences [3].
During a normal pregnancy, insulin resistance is observed during the first trimester. To
maintain normoglycemia during the pregnancy, insulin release is increased significantly [4].
Women unable to adapt to such pregnancy-induced physiological changes in insulin sensi-
tivity are at risk of developing GDM [5].
Despite normalization of glucose tolerance shortly after delivery, women with a history of
GDM have increased risk of developing diabetes later in life. A systematic review and ameta-
analysis including 675,455 women reported a sevenfold risk of developing diabetes among
women with a history of GDM compared with women having a normoglycemic pregnancy in
studies with follow-up times up to 30 years after index pregnancy [6]. In Denmark, 40% of 481
women with a history of diet-treated GDM had developed type 2 diabetes 10 years after their
index pregnancy [7]. Apart from risk of diabetes later in life, there are additional compli-
cations for mothers having GDM such as increased risk of undergoing caesarean section and
pre-eclampsia, whereas the child is at risk for macrosomia, shoulder dystocia, neonatal
hypoglycemia, and development of obesity and prediabetes in young adulthood [5, 8].
A family history of diabetes has been established as a nonmodifiable risk for GDM [9].
Shared genetics with both type 1 diabetes, type 2 diabetes, and monogenic forms of diabetes
has been suggested as the underlying genetic etiology for GDM [10].
Cross-sectional studies estimating the presence of mutations in maturity-onset diabetes
of the young (MODY) genes among women with GDM have found prevalences between 0%
and 5% of GCK mutations in studies including between 17 and 247 individuals, depending
on inclusion criteria [11–17]. One study found a prevalence of 80% GCK mutations when
stringent selection criteria were applied [18]. The prevalence of HNF1A and HNF4A
mutations among GDM women have been estimated in a few studies including between 66
and 119 women with GDM. It was found that 0% to 1% of GDM can be attributed to del-
eteriousHNF1A orHNF4Amutations in women having a positive family history of diabetes
[13, 14].
The aim of the current study was to screen for variants inGCK,HNF1A,HNF4A,HNF1B,
and INS and establish the prevalence of disease-associated variants in a large study cohort of
354 consecutively recruited Danish women diagnosed with diet-treated GDM. Furthermore,
we also estimated the impact ofGCK,HNF1A,HNF4A,HNF1B, or INSmutations on glucose
tolerance at follow-up examination on average 9.8 years after the index pregnancy to identify
the risk of progression to diabetes among GDM women with and without disease-associated
variants.
1. Methods
Womendiagnosedwith diet-treatedGDMwere recruited for the study between 1978 and 1985
and 1987 and 1996 at the Center for Pregnant Women with Diabetes, Department of Ob-
stetrics, Rigshospitalet, Denmark [7]. The women were invited to a follow-up study between
2000 and 2002 investigating their glucose tolerance status. We included 354 Danish women
with diet-treated GDM in the current study. The median follow-up time was 9.8 years after
the index pregnancy [7]. All women were glutamic acid decarboxylase antibody (GADA)
negative (Table 1).
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A. Anthropometrical Measures and Biochemical Measures at Follow-Up
The women had two blood samples drawn from an antecubital vein for measurement of
plasma glucose, serum insulin, and serum GADAs after 10 hours of fasting. Women without
known diabetes underwent a 2-hour, 75-g oral glucose tolerance test. Diabetes at follow-up
was classified according to American Diabetes Association criteria [19], and prediabetes was
defined as either impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), or both.
Plasma glucose was measured by the glucose oxidase method using an automated col-
orimetricmethod on aCobasMira analyzer. GADAswere detected by a radioimmunoassay [7,
20]. The cutoff limit was 9.5 units/mL, and the intra- and interassay coefficients of variation
were 0.024 and 0.036, respectively. High-sensitivity CRP (hsCRP) was measured on a Roche/
Hitachi MODULAR analyzer (Tina-quant cardiac C-reactive protein high sensitive, cobas,
Roche) with a measuring range of 0.1 to 20 mg/L.
B. Diabetes Family History
Based on questionnaires, information on family history of diabetes was divided into three
categories: parental diabetes, no parental diabetes, and unknown.
C. Sequencing
Genomic DNA was obtained from human leukocyte nuclei. DNA in the targeted region,
which included the coding regions and exon/intron boundaries of GCK, HNF1A, HNF4A,
HNF1B, and INS genes, was captured and sequenced using the Illumina HiSeq2000
Analyzer as described [21]. All coding regions were covered with a minimummean depth of
763. Qualified reads were aligned to the reference human genome (UCSC hg19) using the
Burrows-Wheeler Aligner tool (http://bio-bwa.sourceforge.net), and single-nucleotide
polymorphisms and indels were identified using the Genome Analysis Toolkit (https://
www.broadinstitute.org/gatk/).
D. Evaluation of Variant Pathogenicity
Variants located in coding regions, -10 nucleotides upstream of the transcription start site
or 5 nucleotides into intron boundaries, were evaluated. Nonsynonymous variant patho-
genicity was evaluated as described [22] (Supplemental Tables 1 and 2). This includes
the previous establishment of the variant’s deleterious effect, the frequency in public
Table 1. Clinical Description of the Total Study Population at Follow-Up
Traits GAD Negative (n = 354)
Age (y) 43.0 (37.0–48.0)
BMI (kg/m2) 27.6 (23.9–32.9)
Waist/hip ratio 0.82 (0.78–0.87)
HbA1C (%) 5.4 (5.0–6.1)
HbA1C (mmol/mol) 35.5 (31.1–43.2)
Fasting plasma glucose (mmol/L) 6.3 (5.69–7.50)
Fasting serum insulin (pmol/L) 54 (35–79)
GADAs (% of total population) 0%
Parental diabetes (yes/no/unknown) 161/150/43
Glucose-tolerant [% (n)] 17% (n = 60)
IFG [% (n)] 26% (n = 92)
IGT [% (n)] 19% (n = 67)
Diabetes [% (n)] 38% (n = 135)
Data are presented as median and interquartile range.
Abbreviation: GAD, glutamic acid decarboxylase.
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databases, the level of computational evidence for functionality, and the patient’s phe-
notype, among other criterions. The cutoff for frequency in public databases was defined
as a minor allele frequency# 0.05% in the ExAC database (http://exac.broadinstitute.org/)
and absence of the variant among 1000 glucose-tolerant Danes [23]. The patient’s phe-
notype was included (1) for GCK if carriers had a fasting plasma glucose above 5.5 mmol/L
at follow-up, as elevated fasting glucose levels are a phenotypic characteristic for GCK
MODYpatients [24], and (2) forHNF1A variants if carriers had a plasma glucose increment
after an oral glucose load [plasma glucose 120 minutes after an oral glucose load (fasting
plasma glucose)] above 3 mmol/L [25] or a level of hsCRP below 1 mg/L [26], which are
phenotypic characteristics of HNF1A patients. The criteria for computational evidence for
functionality were applied if the variant was predicted to be damaging in three or more of
the following programs: SIFT [27], PolyPhen2 HVAR [28], LRT [29], MutationTaster [30],
MutationAssessor [31], and FATHMM [32]. Splice variants were classified as func-
tional according to Human Splicing Finder (www.umd.be/HSF3/index.html) [33], and 5-
untranslated region functionality was based on the effect on transcription factor binding sites
using the JASPAR database (http://jaspar.genereg.net/).
E. Statistical Analysis
To test quantitative traits for differences between groups, a general linear model was used,
adjusted for age. The difference in the prevalence of diabetes between groups was calculated
using a x2 test, with a P value of 0.05 considered to be significant.
2. Results
Screening ofGCK,HNF1A,HNF4A, INS, andHNF1B in 354 GDMwomen revealed a total of
50 different variants in the target region (Supplemental Table 1), of which 17 were classified
as pathogenic or possibly pathogenic. The variants were found in 21 patients, resulting in a
5.9% (95% CI: 3.5% to 8.4%) prevalence of possible diabetes-predisposing gene variants
(Fig. 1).
A. Variants Identified in GCK
Six possibly pathogenic GCK variants were found in seven individuals. Four carriers were
diagnosedwith diabetes previous to follow-up; yet, at follow-up, all carriers had overt diabetes
or prediabetes (Supplemental Table 2). Of the four patients with diagnosed diabetes, one
received insulin treatment. The remaining three diagnosed patients were either diet treated
(n = 2) or treated with an oral hyperglycemic agent (OHA) (n = 1). When comparing the
phenotypic characteristics, hemoglobin A1c (HbA1c) was significantly higher in women with
Figure 1. Schematic presentation of the prevalence of GDM patients with diabetes-
predisposing variants in GCK, HNF1A, HNF4A, HNF1B, or INS in the total GDM population
and the distribution of glucose tolerance status.
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GCK variants [6.1% (6.1 to 6.8)] compared with women without MODY gene variants [5.4%
(5.0 to 6.1]);P = 0.04), whereas no other clinical features at follow-up differentiated from those
of women without diabetes-predisposing variants (Table 2).
Table 2. Summarized Phenotypic Characteristics of Women With Diabetes-Predisposing Variants and
Women Without
GCK
Variant
Carriers
(n = 7)
HNF1A
Variant
Carriers
(n = 7)
HNF4A
Variant
Carriers
(n = 6)
INS
Variant
Carrier
(n = 1)
MODY Gene
Variant
Carriers
(Group 1)
(n = 21)
GAD-
Negative
Women
With
No Variants
(Group 2)
(n = 333)
P
Value,
Group
1 vs
Group
2
Age (y) 47.0
(41.3–50.0)
42.0
(38.0–43.0)
47.5
(42.3–49.8)
41 43.0
(41.00–49.0)
43.0
(37.0–48.0)
0.9
Weight
prepregnancy
(kg)
68.0
(59.5–91.0)
71.0
(60.0–83.5)
72.0
(62.0–103)
73.9 72.0
(59.5–89.5)
68.00
(60.0–83.0)
0.6
Weight at
follow-up (kg)
97.0
(68.4–102)
73.9
(62.1–87.4)
69.9
(62.1–83.5)
74.1 74.1
(63.5–97.0)
75.1
(65.2–89.0)
1.0
BMI
prepregnancy
(kg/m2)
24.2
(21.9–33.6)
24.2
(23.4–24.4)
24.3
(22.5–37.8)
26.2 24.3
(22.6–30.8)
24.6
(21.6–29.8)
0.5
BMI at
follow-up
(kg/m2)
36.2
(25.7–37.2)
25.6
(24.9–29.3)
25.8
(22.9–31.3)
27.6 27.5
(24.3–33.1)
27.6
(23.9–32.9)
1.0
Waist/hip ratio 0.83
(0.81–0.86)
0.83
(0.80–0.86)
0.89
(0.80–0.92)
0.85 0.84
(0.79–0.88)
0.82
(0.78–0.87)
0.5
HbA1C (%) 6.10
(6.10–6.75)a
5.40
(5.05–6.70)
7.25
(6.13–9.35)a
5.40 6.10
(5.40–7.10)
5.4
(5.00–6.10)
0.007
Fasting plasma
glucose
(mmol/L)
7.70
(6.85–8.95)
6.20
(6.00–7.65)
9.30
(7.92–13.4)a
5.90 7.68
(6.05–9.83)
6.20
(5.68–7.29)
0.04
Fasting serum
insulin
(pmol/L)
51.0
(29.3–72.3)
62.3
(41.5–78.1)
41.3
(20.5–74.0)
62.0 54.8
(31.0–80.1)
53.25
(35.5–76.0)
0.4
Fasting plasma
HDL (mmol/L)
1.45
(1.23–1.67)
1.44
(1.38–1.52)
1.46
(1.11–1.85)
1.72 1.45
(1.23–1.72)
1.45
(1.22–1.75)
0.7
Fasting plasma
triglycerides
(mmol/L)
0.75
(0.73–1.18)
1.22
(1.06–1.29)
0.98
(0.73–1.24)
0.78 1.02
(0.74–1.25)
1.29
(0.92–1.90)
0.02
Fasting plasma
FFA (mmol/L)
0.52
(0.43– 0.70)
0.67
(0.48–0.88)
0.70
(0.61–0.77)
0.57 0.63
(0.51–0.77)
0.57
(0.42–0.75)
0.9
Serum hsCRP
(mg/L)
4.90
(1.19–8.83)
0.61
(0.54–2.69)
1.75
(0.85–9.83)
7.58 1.74
(0.57–6.75)
1.86
(0.88–4.79)
0.6
Family history
(n)
Noparental: 3 Noparental: 3 Noparental: 1 Parental
diabetes
No parental: 7 No parental:
154
0.4
Parental: 3 Parental: 2 Parental: 4 Parental: 10 Parental: 140
Unknown: 1 Unknown: 2 Unknown: 1 Unknown: 4 Unknown: 39
Treatment
before
follow-up (n)
Diet: 2 Diet: 0 Diet: 2 NA Diet: 4 Diet: 19 0.01
OHA: 1 OHA: 0 OHA: 4 OHA: 5 OHA: 25
Insulin: 1 Insulin: 1 Insulin: 0 Insulin: 2 Insulin: 14
Diabetes
status at
follow-up
(ADA)
Glucose-
tolerant: 0
Glucose-
tolerant: 1
Glucose-
tolerant: 0
Glucose-
tolerant: 0
Glucose-
tolerant: 1
Glucose-
tolerant: 59
0.002
Prediabetes:
2
Prediabetes:
2
Prediabetes:
0
Prediabetes:
1
Prediabetes:
5
Prediabetes:
155
Diabetes: 5 Diabetes: 4 Diabetes: 6 Diabetes: 0 Diabetes: 15 Diabetes: 120
Data are presented as median and interquartile range.
Abbreviations: ADA, American Diabetes Association; FFA, free fatty acids; NA, not applicable.
aP , 0.05.
doi: 10.1210/js.2017-00040 | Journal of the Endocrine Society | 685
Downloaded from https://academic.oup.com/jes/article-abstract/1/6/681/3769967
by Kobenhavns Universitets user
on 08 March 2018
B. Variants Identified in HNF1A
Five HNF1A diabetes-predisposing variants were found among seven carriers. The Gly288fs*
variant was found in a carrier diagnosed with diabetes prior to follow-up and receiving insulin
treatment (Supplemental Table 2). None of the remaining HNF1A variants carriers were di-
agnosed with diabetes prior to follow-up, despite three of them having overt diabetes and two
being prediabetic. The phenotype of HNF1A variant carriers did not differ significantly from
those of women not carrying diabetes-predisposing variants (Table 2).
C. Variants Identified in HNF4A
FiveHNF4A diabetes-predisposing variants were found in a total of six individuals (Table 2).
These individuals were all diagnosed with diabetes before follow-up. Two were diet treated,
whereas the remaining four were treated with an OHA (Table 2); however, there is no in-
formation on the type of OHA selected. Despite diagnosing the patients before follow-up,
fasting plasma glucose and HbA1c were significantly higher among the women with HNF4A
variations [9.3 mmol/L (7.9 to 13.4) and 7.3% (5.7 to 7.3)] compared with women without [6.2
mmol/L (5.7 to 7.3) and 5.4% (5.0 to 7.3) P = 0.03 and P = 0.01, respectively] (Table 2).
D. Variants Identified in HNF1B
None of the two identified nonsynonymous variants in HNF1B were classified as diabetes
predisposing (Supplemental Table 1).
E. Variants Identified in INS
Four variants were found in INS, of which one was classified as a diabetes-predisposing
variant (Supplemental Table 1). This individual was 41 years of age and had prediabetes
and a father with diabetes (Table 2; Supplemental Table 2).
F. Carriers vs Noncarriers
At follow-up, we compared the phenotypes of women with variants in the examined MODY
genes to women without and found that women having variants in MODY genes had a higher
level of fasting plasma glucose (P = 0.01) and HbA1c (P = 0.007) (Table 2). In addition, their
levels of triglycerides were reduced compared with women without variants in the in-
vestigated genes (P = 0.02). None of the remaining biochemical or anthropometricalmeasured
traits discriminated variant carriers from women with no MODY gene variants, including
family history of diabetes (Table 2). Yet, despite an insignificant difference, 95% (n = 20) of
women with diabetes-predisposing variants had IGT, IFG, or diabetes at follow-up compared
with only 82% (n = 275) among women without variants (P = 0.1) (Table 2).
In total, 135 women had diabetes at follow-up either based on diagnosis before follow-up
examination or based on the performed oral glucose tolerance test. Fifteen out of these 135
(11%) were carriers of MODY gene variants. Thus, the prevalence of diabetes at follow-up
among individuals not carryingMODYgene variants was 36% (95%CI: 31% to 41%) (n = 120),
in contrast to 71% (95% CI: 52% to 91%) (n = 15) in carriers, revealing a significant difference
in diabetes prevalence between these two groups (P = 0.002) (Fig. 1; Table 2). However, the
phenotypic characteristics of the 15 diabetic women having variants in MODY genes did not
differ from the remaining 120 women with diabetes at follow-up (Supplemental Table 3).
3. Discussion
In the current study, we found a 5.9% prevalence of diabetes-predisposing variants in GCK,
HNF1A, HNF4A, HNF1B, or INS among women diagnosed with diet-treated GDM. Fur-
thermore, 71% ofwomenwith variants in the examinedMODYgenes had diabetes at 10-years
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follow-up compared with only 36% of the women not having variants in these genes. Thus,
11% of the total number of diabetic women at follow-up had diabetes-predisposing variants in
GCK,HNF1A,HNF4A,HNF1B, or INS. This result also reveals that a segment of the carriers
do not develop diabetes within 10 years follow-up. Yet, 95% of carriers had a dysregulated
glucose metabolism, with only one individual being normoglycemic at follow-up among
variant carriers. A previous study found a 0.5%and 1.5%prevalence of likely diabetes-causing
variants in HNF1A, GCK, HNF4A, and HNF1B in two community-based study populations
[34], with a large proportion of carriers being normoglycemic. Thus, nondiabetic variant
carriers have been encountered in previous studies of unselected populations.
Most previous studies have included fewer GDMwomen than the present, and no study has
investigated the combined prevalence of mutations in common MODY genes among GDM
patients. The prevalence of diabetes-predisposing GCK variants in the current study is
consistent with previous studies ofGCK variants among GDMwomen. In contrast, among the
few previous studies investigating the prevalence of HNF1A and HNF4A variants in women
with GDM, lower prevalences have been found. These studies were performed in GDMwomen
with a positive family history. This may suggest that selecting patients based on a family
history underestimates the prevalence of diabetes-predisposing variants and enriches for
more penetrant mutations. This is in line with our finding that a positive family history of
diabetes is not a marker for carriers of diabetes-predisposing variants in our study. The
prevalence of HNF1A and HNF4A diabetes-predisposing variants is similar to what was
reported in a population-based study of rare variants in genes for a dominant Mendelian form
of diabetes [34]. Interestingly, a recent study of the genetic architecture of type 2 diabetes
identified awidespread enrichment for type 2 diabetes association among rare coding alleles in
genes that are causal for monogenic diabetes [35]. Age of diabetes diagnosis was no lower in
variant carriers than noncarriers. In line with the studies of the genetic architecture of type 2
diabetes, the variants identified among GDM women in the current study do not likely have
sufficient penetrance to drive familial segregation or early-onset diabetes, but still they in-
crease the predisposition to diabetes. Furthermore, GDM HNF1A variant carriers have de-
creasedhsCRP comparedwith carriers of variants in other genes, indicating that the identified
HNF1Amutations are functional. Yet, hsCRP levels are higher than reported amongHNF1A
MODY patients [26]. This further indicate that the variants are diabetes predisposing but not
of sufficient penetrance to cause clinical MODY.
New pregnancy-specific screening criteria have been suggested to identify women with
GCKMODY. The criteria include a fasting plasma above 5.5 mmol/L during pregnancy and a
prepregnancy body mass index (BMI) ,25 kg/m2 as the best discriminators between MODY
and GDM [15]. However, we did not find that prepregnancy BMI below 25 kg/m2 improved
diagnosis of GDM women carrying GCK mutations (Table 2; Supplemental Table 2).
We establish that close to 6% of the women having diet-treated GDM have diabetes-
predisposing variants in the examined MODY genes. Diagnosing such variants in women
with GDM might be important in relation to treatment. Discontinuation of treatment after
pregnancy in the two women carrying GCK variants and receiving insulin and OHA treatment,
respectively, should be considered. However, this should be evaluated in the light of other
phenotypic characteristic suchas fastingplasmaglucose of 12.1mmol/LandaBMIof 37kg/m2, in
which case, type 2diabetes in addition toGCKMODYshould be considered.Diagnosingdiabetes-
predisposing variants inMODYgenes amongpatientswithGDMmight be important not only for
treatment during pregnancy, but also for treatment and prognosis of GDMwomen after delivery.
A limitation to this study is the lack of direct functional investigation of all identified
variants, which may result in the exclusion of truly functional variants and the inclusion of
nondeleterious variants. However, using stringent selection criteria for the classification of
pathogenic variants based on variant location, type of variant, allele frequency, absence in
healthy controls, previous described involvement in MODY, functionality, and phenotypic
presentation of carriers, we believe we have circumvented this issue to a large extent.
Womenwere selected only if they had been diagnosedwith diet-treatedGDM.Wemayhave
identified a higher prevalence of especially non-GCK MODY if women diagnosed with more
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severe insulin-treated forms of GDM also been included in this study. Approximately 15% of
GDM women were treated with insulin at the center from which the women in the current
study were recruited [7]. Selecting only women with diet-treated GDM may also have
introduced a bias toward identification of less pathogenic variants, as the effects of the
variants as mentioned are likely a spectrum with various effect sizes.
4. Conclusion
With almost 6%ofDanishwomenwith diet-treatedGDMhaving diabetes-predisposing variants
in GCK, HNF1A, HNF4A, HNF1B, or INS, this study indicates that an increased focus on
screening these MODY genes among women with GDM is warranted. Correct diagnosis is
important to ensure optimal counseling and treatment during pregnancy as well as identifying
women having a significant increased risk of developing diabetes only a few years after delivery.
Furthermore, diagnosis is important in relation to the screening of children of MODYmutation
carriers, which could help early treatment initiatives in the offspring generation. Further
studies of the impact on disease history and treatment response of variants identified in GCK,
HNF1A, HNF4A, HNF1B, or INS among women with GDM are warranted.
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